On April 27, 2024, the "Clinical Technology Training Course for DRG Electrical Stimulation Pain Treatment · Henan Station," hosted by the First Affiliated Hospital of Zhengzhou University and co-organized by Rishena Medical, successfully concluded.The training course was chaired by Director Fan Xiaochong from the Pain Department of the First Affiliated Hospital of Zhengzhou University. Professor Zhao Jie, Party Committee Deputy Secretary and Vice President of the First Affiliated Hospital of Zhengzhou University, attended the meeting and delivered a welcome speech. The training course invited Dr. Cong Yu from the Swedish Medical Center in Seattle, USA, Professor Ren Yu'e from the Pain Department of the Second Hospital of Hebei Medical University, and Associate Chief Physician Kong Cunlong from the Pain Department of the First Affiliated Hospital of Zhengzhou University as speakers. Over 100 physicians from across China participated in this training course."TheoryCombined with practical operation, Systematic Sharing of Clinical Experience"
During this training course, the team led by Director Fan Xiaochong from the Pain Department of the First Affiliated Hospital of Zhengzhou University systematically and comprehensively demonstrated the full process of DRG electrical stimulation and conventional SCS surgeries to the attending physicians through live surgical broadcasts.| DRG Electrical Stimulation Surgery Demonstration |
Case 1
Case 2
Case 3
| Routine SCS Surgery Demonstration |
Case 4
The speakers of the meeting shared their insights on the progress of DRG electrical stimulation applications, surgical techniques, and clinical experiences, among others. In particular, Dr. Yu Cong from the Swedish Medical Center in Seattle, USA, shared the current status and advancements of SCS therapy, including DRG electrical stimulation, in the United States, which attracted widespread attention and in-depth discussion from the attending physicians.
Yu Cong
Swedish Medical Center, Seattle, USA
Fan Xiao Chong
The First Affiliated Hospital of Zhengzhou UniversityThe Second Hospital of Hebei Medical UniversityThe First Affiliated Hospital of Zhengzhou University
Training Base Plaque Awarding
"About DRG Electrical Stimulation"
DRG electrical stimulation has been clinically applied for over 10 years internationally and is considered the first-line treatment for Type I or Type II complex regional pain syndrome in the lower limbs. It has also demonstrated good therapeutic effects in various refractory pain conditions, such as diabetic peripheral neuropathy and groin pain. Due to the anatomical limitations surrounding the DRG, the electrodes placed within it are less prone to displacement, ensuring stability in both the coverage area of the current and the intensity of electrical stimulation. Additionally, the cerebrospinal fluid enveloping the dorsal root ganglion neurons forms a shallow groove locally, reducing current dispersion and limiting the transmission of stimulation signals to surrounding tissues. This provides precise and stable paresthesia to the painful area while minimizing abnormal sensations in non-painful regions and conserving battery power. Moreover, dorsal root ganglion electrical stimulation can achieve stable current coverage in areas such as the lower back and feet, which is difficult to achieve with conventional SCS.Rishena Medical has the only electrode in China with a diameter of 1.0mm approved for dorsal root ganglion (DRG) puncture. Used with a dedicated tool kit, it can be precisely implanted into areas such as the dorsal root ganglion, trigeminal ganglion, and sacral nerve. DRG electrical stimulation surgeries have been performed in multiple hospitals across China, achieving favorable therapeutic outcomes.Rishena Medical Co., Ltd. is an innovative high-tech enterprise specializing in the research, development, production, and sales of active implantable medical devices.
The company originated from the industrial-academic transformation of an implantable neural stimulator project by a team from Tsinghua University's Microelectronics Institute. It settled in 2013 within the national-level development zone in Changzhou, Jiangsu Province. The founding team graduated from Tsinghua University and was co-founded with the participation of Tsinghua Venture Capital and listed companies.
The company has a high-level R&D, production, quality control, clinical and marketing team, with more than 100 patents. It has received support from national key R&D projects, the Brain Project, provincial innovation and entrepreneurship teams, and other government programs multiple times. Additionally, it was successfully selected as one of "Jiangsu Province's Potential Unicorn Enterprises in 2023."
For many years, Rishena Medical has been actively involved in key areas of brain science research, providing comprehensive solutions for disease treatment. The company's self-developed implantable vagus nerve stimulator (VNS), single-use intracranial electroencephalogram electrodes (SEEG), implantable rechargeable spinal cord stimulator (SCS), and transcutaneous auricular vagus nerve stimulator (t-VNS) have been approved and launched in the market. The implantable closed-loop neurostimulator (CNS) is about to be launched, and the intrathecal drug delivery system (IDDS) is awaiting entry into the clinical trial stage. In the future, more innovative products that effectively address clinical needs will be introduced.
Rishena Medical always adheres to the quality policy of "Valuing quality is caring for life," placing product quality as the top priority, constantly refining product quality, with the goal of becoming China's most outstanding active implantable medical device enterprise.
Statement: The intellectual property rights of the content published by Neuromedical Hub, including Neurosurgery Information, Neurointervention Information, Neuromedical Consultation, and AiBrain, belong to Neuromedical Hub, the organizers, original authors, and other relevant right holders. Without permission, reproduction, excerpting, copying, cropping, recording, etc., are prohibited. Even with authorized use, the source must be cited. Forwarding and sharing are welcome.
For submission/conference release, please contact 400-888-2526 ext. 3
Brain Medicine HubApp (OriginalNeurosurgery Information/Neurointerventional InformationApp）“"Topic Circle"重磅 launched online, here you can find various professional questions and authoritative answers, click "Read the Original Text"First Access!"
